Codiak Biosciences Inc Revenue Growth Rates (CDAK), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Codiak Biosciences Inc   (NASDAQ: CDAK)
 

CDAK's Revenue Growth by Quarter and Year

Codiak Biosciences Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CDAK Revenue (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
4th Quarter December -
3rd Quarter September 0.52
2nd Quarter June 13.15
1st Quarter March 12.70
FY 26.37





CDAK Revenue third quarter 2022 Y/Y Growth Comment
Codiak Biosciences Inc reported drop in Revenue in the third quarter 2022 by -55% to $ 0.52 millions, from the same quarter in 2021.
The fall in the third quarter 2022 Codiak Biosciences Inc 's Revenue compares unfavorably to the Company's average Revenue doubling of 334.92%.

Looking into third quarter 2022 results within Biotechnology & Pharmaceuticals industry 67 other companies have achieved higher Revenue growth. While Codiak Biosciences Inc ' s Revenue meltdown of -55% ranks overall at the positon no. 3839 in the third quarter 2022.


CDAK Revenue ( Y/Y Growth %) 2022
 2021 2020 2019
4th Quarter December - 369.51 % 993.33 % -
3rd Quarter September -55 % 22.11 % - -
2nd Quarter June 1377.53 % 368.42 % - -
1st Quarter March -3.71 % 10046.15 % - -
FY   - 688.32 % 1840 % -

Financial Statements
Codiak Biosciences Inc 's third quarter 2022 Revenue $ 0.52 millions CDAK's Income Statement
Codiak Biosciences Inc 's third quarter 2021 Revenue $ 1.16 millions Quarterly CDAK's Income Statement


CDAK Revenue (Quarter on Quarter Growth %)

 2022
 2021 2020 2019
4th Quarter December - 563.79 % 72.63 % -
3rd Quarter September -96.03 % 30.34 % 400 % -
2nd Quarter June 3.54 % -93.25 % 46.15 % -
1st Quarter March 64.94 % 704.27 % -13.33 % -
FY (Year on Year)   - 688.32 % 1840 % -


Back to CDAK Growth rate Comparisons >> Back to CDAK Growth rate Comparisons >>


Revenue third quarter 2022 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #68
Healthcare Sector #590
Overall #3839

Revenue Y/Y Growth Statistics
High Average Low
1376.97 % 334.92 % -54.88 %
(Jun 30 2022)   (Sep 30 2022)
Revenue third quarter 2022 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #68
Healthcare Sector #590
Overall #3839
Revenue Y/Y Growth Statistics
High Average Low
1376.97 % 334.92 % -54.88 %
(Jun 30 2022)   (Sep 30 2022)

Revenue by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Codiak Biosciences Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
565.25 % 79.08 % -96.03 %
(Dec 31 2021)  


CDAK's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2022 Codiak Biosciences Inc disclosed fall in Revenue from the second quarter by -96.03% to $ 0.52 millions, from $ 13.15 millions achived in the previous reporting period.

Although periodic circumstance commonly energize III. Quarter 2022 Revenue, this plainly could not be substantial to rescue Biotechnology & Pharmaceuticals's company achievement, Most analysts pointed out.

Within Biotechnology & Pharmaceuticals industry 130 other companies have achieved higher Revenue quarter on quarter growth. While Codiak Biosciences Inc 's Revenue growth quarter on quarter, overall rank is 2903.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #131
Healthcare Sector #511
Overall #2903
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #131
Healthcare Sector #511
Overall #2903
Revenue Q/Q Growth Statistics
High Average Low
565.25 % 79.08 % -96.03 %
(Dec 31 2021)  


CDAK's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2022 Codiak Biosciences Inc disclosed fall in Revenue from the second quarter by -96.03% to $ 0.52 millions, from $ 13.15 millions achived in the previous reporting period.

Although periodic circumstance commonly energize III. Quarter 2022 Revenue, this plainly could not be substantial to rescue Biotechnology & Pharmaceuticals's company achievement, Most analysts pointed out.

Within Biotechnology & Pharmaceuticals industry 130 other companies have achieved higher Revenue quarter on quarter growth. While Codiak Biosciences Inc 's Revenue growth quarter on quarter, overall rank is 2903.


Codiak Biosciences Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2022)		 12 Months Ending
(Jun 30 2022)		 12 Months Ending
(Mar 31 2022)		 12 Months Ending
(Dec 31 2021)		 12 Months Ending
(Sep 30 2021)
Cumulative Revenue 12 Months Ending $ 34.07 $ 34.70 $ 22.45 $ 22.94 $ 16.88
Y / Y Revenue Growth (TTM) 101.85 % 108.11 % 40.55 % 686.79 % 1083.59 %
Year on Year Revenue Growth Overall Ranking # 132 # 67 # 0 # 0 # 0
Seqeuential Revenue Change (TTM) -1.83 % 54.59 % -2.12 % 35.89 % 1.22 %
Seq. Revenue Growth (TTM) Overall Ranking # 352 # 378 # 1094 # 83 # 40


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2022 period, Codiak Biosciences Inc 's cumulative twelve months Revenue were $ 34 millions, company would post below average annual Revenue growth of 1.22% year on year, if the fiscal year would end at Sep 30 2022.
A slow-down in the Codiak Biosciences Inc 's Revenue growth from the 16.675% growth in Jun 30 2022.

In the Healthcare sector 38 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 67 to 132.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 85
Healthcare Sector # 39
Overall # 132

Revenue TTM Y/Y Growth Statistics
High Average Low
146.45 %
 142.48 %
138.5 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 45
Sector # 420
S&P 500 # 3067
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2022 period, Codiak Biosciences Inc 's cumulative twelve months Revenue were $ 34 millions, company would post below average annual Revenue growth of 138.5% year on year, if the fiscal year would end at Sep 30 2022.
A slow-down in the Codiak Biosciences Inc 's Revenue growth from the 16.675% growth in Jun 30 2022.

In the Healthcare sector 38 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 67 to 132.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 85
Healthcare Sector # 39
Overall # 132

Revenue TTM Y/Y Growth Statistics
High Average Low
146.45 %
142.48 %
138.5 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 45
Sector # 420
S&P 500 # 3067




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
CDAK's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Sep 30 2022 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2022
Nrc Health-0.20%$ -0.201 millions
Livanova Plc-0.24%$ -0.241 millions
Healthcare Services Group Inc -0.27%$ -0.265 millions
Catalent Inc -0.29%$ -0.293 millions
Asensus Surgical Inc -0.31%$ -0.311 millions
Liquidia Corporation-0.43%$ -0.429 millions
Integra Lifesciences Holdings Corp-0.43%$ -0.432 millions
Pediatrix Medical Group Inc -0.62%$ -0.615 millions
China Pharma Holdings Inc-0.64%$ -0.642 millions
Acadia Pharmaceuticals Inc -0.68%$ -0.682 millions
Bausch and Lomb Corp-0.74%$ -0.738 millions
Amgen Inc -0.81%$ -0.805 millions
Syneos Health Inc -0.89%$ -0.891 millions
Hologic Inc-0.93%$ -0.925 millions
Innovage Holding Corp -1.07%$ -1.070 millions
Regen Biopharma Inc -1.09%$ -1.088 millions
Procyon Corporation-1.20%$ -1.200 millions
Precipio inc -1.38%$ -1.380 millions
Ati Physical Therapy Inc -1.40%$ -1.397 millions
Ocular Therapeutix Inc -1.55%$ -1.547 millions
Alpine Immune Sciences Inc -1.75%$ -1.750 millions
Surgalign Holdings Inc -1.79%$ -1.786 millions
Tenet Healthcare Corp-1.90%$ -1.900 millions
Teleflex Incorporated-1.92%$ -1.923 millions
Novocure Limited-1.95%$ -1.952 millions
Fresenius Medical Care Ag-1.99%$ -1.990 millions
Hca Healthcare Inc -2.00%$ -1.997 millions
Dynatronics Corporation-2.01%$ -2.014 millions
Royalty Pharma Plc-2.10%$ -2.101 millions
National Healthcare Corp-2.13%$ -2.130 millions


About Codiak Biosciences Inc Revenue Growth Rates (CDAK), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Codiak Biosciences Inc (CIK 1659352).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0000950170-22-021879
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Codiak Biosciences Inc ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.